The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
EngstromP.F., BensonA.B.III, CohenA.NCCN colorectal cancer practice guidelines. Oncology.1996; 10(suppl 1): 140–75.
2.
WolmarkN., RocketteH., MamounasE.Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol.1999; 17: 3553–9.
3.
VaughnD.J., HallerD.G.The role of adjuvant chemotherapy in the treatment of colorectal cancer. Hematol Oncol Clin North Am.1997; 11: 699–719.
4.
HallerD.G., CatalanoP.J., MacdonaldJ.S.Fluorouracil (FU), leucovorin (LV), and levamisole (LEV) adjuvant therapy for colon cancer: Five-year final report of INT-0089. Proc Am Soc Clin Oncol.1998; 17: 256a.
5.
MachoverD.A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer.1997; 80: 1179–87.
6.
WaddellJ.A., SolimandoD.A.Fluorouracil and low-dose leucovorin (Mayo regimen) for advanced colorectal cancer. Hosp Pharm.2001; 36: 28–32.
7.
HeidelbergerC., ChaudhuriN.K., DannebergP.Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature.1957; 179: 663–6.
8.
MoertelC.G., FlemingT.R., MacdonaldJ.S.Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med.1990; 322: 352–8.
9.
MoertelC.G., FlemingT.R., MacdonaldJ.S.Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med. 1995; 122:321–6.
10.
MooreH.C., HallerD.G.Adjuvant therapy of colon cancer. Semin Oncol.1999; 26: 545–55.
11.
Di CostanzoF., GasperoniS., MalacarneP.High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer. Am J Clin Oncol.1998; 21: 369–75.
12.
BurokerT.R., O'ConnellM.J., WieandH.S.Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol.1994; 12: 14–20.
13.
CaudryM., BonnelC., FloquetA.A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. Am J Clin Oncol.1995; 18: 118–25.
14.
JagerE., HeikeM., BernhardH.Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial. J Clin Oncol.1996; 14: 2274–9.
15.
NobileM.T., RossoR., SertoliM.R.Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur J Cancer.1992; 28A: 1823–7.
16.
LeichmanC.G., FlemingT.R., MuggiaF.M.Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol.1995; 13: 1303–11.
17.
GlimeliusB., JakobsenA., GrafW.Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: A prospective randomised trial. Eur J Cancer.1998; 34: 674–8.
18.
SobreroA.F., AscheleC., BertinoJ.R.Fluorouracil in colorectal cancer – a tale of two drugs: Implications for biochemical modulation. J Clin Oncol.1997; 15: 368–81.
19.
HeskethP.J., KrisM.G., GrunbergS.M., BeckT., HainsworthJ.D., HarkerG.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
20.
American Society of Health-System Pharmacists. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm.1999; 56: 729–64.
21.
National Comprehensive Cancer Network. NCCN antiemesis practice guidelines. Oncology.1997; 11: 57–89.
22.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–94.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18: 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34: 1857–64.
27.
HallerD.G., LefkopoulouM., MacdonaldJ.S.Some considerations concerning the dose and schedule of 5FU and leucovorin: Toxicities of two dose schedules from the Intergroup Colon Adjuvant Trial (INT-0089). Adv Exp Med Biol.1993; 339: 51–6.
28.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
29.
WadlerS., BensonA.B., EngelkingC.Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol.1998; 16: 3169–78.
30.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
31.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and onco-logic agents. Gastroenterol Clin North Am.1995; 24: 969–89.
